1 Min Read
March 15 (Reuters) - Exelixis Inc:
* EXELIXIS SUBMITS U.S. SUPPLEMENTAL NEW DRUG APPLICATION FOR CABOMETYX (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.